Lomond Therapeutics

Lomond Therapeutics is a Boston-based, private, precision hematology company founded in 2021. It is developing a pipeline of small molecule drugs designed to overcome treatment resistance in hematological cancers, with a lead program targeting FLT3/IRAK4 in Acute Myeloid Leukemia (AML). The company's strategy centers on creating 'pan-variant' therapies that inhibit multiple resistance mutations and escape mechanisms simultaneously, aiming to address a critical unmet need in oncology. Leadership includes experienced biotech executives and is backed by venture capital firms like OrbiMed and Teal Ventures.

A biological insight-driven approach focused on developing pan-variant small molecule inhibitors that target both primary oncogenic drivers and key escape/resistance pathways simultaneously to overcome treatment resistance in hematological cancers.

Lomond operates in highly competitive spaces. In FLT3-mutant AML, it faces established drugs (quizartinib, gilteritinib) and numerous next-generation candidates. In BCL2 inhibition, it competes with the blockbuster venetoclax and its successors. Lomond's differentiation hinges on demonstrating superior durability through its pan-variant/escape mechanism targeting, a claim yet to be clinically proven.